La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Daxor Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Daxor ha un patrimonio netto totale di $34.0M e un debito totale di $755.7K, che porta il suo rapporto debito/patrimonio netto a 2.2%. Le sue attività totali e le sue passività totali sono rispettivamente $34.9M e $858.8K.

Informazioni chiave

2.2%

Rapporto debito/patrimonio netto

US$755.66k

Debito

Indice di copertura degli interessi	n/a
Contanti	n/a
Patrimonio netto	US$34.01m
Totale passività	US$858.76k
Totale attività	US$34.87m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { DXR di $25.9K ) non coprono le sue passività a breve termine ( $103.1K ).

Passività a lungo termine: Le attività a breve termine di DXR ( $25.9K ) non coprono le sue passività a lungo termine ( $755.7K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 2.2% ) di DXR è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di DXR si è ridotto da 34.1% a 2.2% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di DXR è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di DXR siano ben coperti dall'EBIT.

Daxor Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Recent updates

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 16%

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Investor sentiment improves as stock rises 20%

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 26%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorated over the past week

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $2.000007 million.

Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure

Investor sentiment deteriorated over the past week

Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay (LOS) for Heart Failure (HF) Patients

Daxor Corporation to Report Q2, 2022 Results on Aug 25, 2022

Daxor reports Q2 results

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Daxor Corporation Announces New Data Demonstrating the Importance and Clinical Utility of Daxor’s Bva-100 Blood Test in Heart Failure (Hf) Patients Published in the Journal of Cardiac Failure

Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Daxor Corporation Provides Update on American College of Cardiology (ACC) Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Daxor Corporation Announces the Initiation of A Multi-Center Clinical Trial with Two Veterans Affairs Medical Centers to Evaluate Blood Volume Analysis Guided Management of Acute Decompensated Heart Failure Utilizing the BVA-100 Blood Test

Daxor Corporation Announces Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation Announces Novel Fluorescent Tracer and Phase-Two US Air Force Contract Award of $750,000 for Point-Of-Care Optical Blood Volume Analyzer

Revenue and earnings miss expectations

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

New 90-day low: US$11.49

Daxor Corporation Announces New Data from the University of Hawaii John A. Burns School of Medicine Showing the BVA-100 Blood Test

Daxor Corporation Announces New Distribution Agreement with L1 Enterprises Government Distributor

New 90-day low: US$12.10

New 90-day low: US$12.55

Wake Forest Baptist Health Joins Multicenter Covid-19 Bva-100 Blood Test Study

New 90-day low: US$13.85

New 90-day low: US$14.61

Daxor Corporation Announces Compelling New Data Demonstrating Further Beneficial Use of Blood Volume Analysis Technology Presented During the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane